Get the Stockscreener App
17.37
1.72%
-0.39
Definium Therapeutics Inc stock is traded at $17.37, with a volume of 914.66K.
It is down -1.72% in the last 24 hours and up +7.42% over the past month.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
See More
Previous Close:
$17.76
Open:
$17.62
24h Volume:
914.66K
Relative Volume:
1.10
Market Cap:
$1.71B
Revenue:
-
Net Income/Loss:
$-168.10M
P/E Ratio:
-8.8065
EPS:
-1.9724
Net Cash Flow:
$-113.89M
1W Performance:
+0.95%
1M Performance:
+7.42%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$17.12
$18.07
1-Week Range:
$16.55
$18.56
52-Week Range:
$14.62
$18.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
17.36 | 1.75B | 0 | -168.10M | -113.89M | -1.9724 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.24 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.48 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (DFTX) Latest News
Q1 EPS Forecast for Definium Therapeutics Cut by Analyst - MarketBeat
Number of shareholders of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics Inc: DT120's robust efficacy and rapid adoption potential position it as a transformative psychiatric therapy - TradingView
Definium Therapeutics Inc: DT120 demonstrated unprecedented efficacy in GAD and MDD, with broad adoption anticipated - TradingView
DFTX: HC Wainwright & Co. Raises Price Target to $70 | DFTX Stoc - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks - Yahoo Finance
DFTX Technical Analysis & Stock Price Forecast - Intellectia AI
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus - Sahm
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - Newswire Canada
Is Rising 2025 Loss and Investor Outreach Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
DFTX Should I Buy - Intellectia AI
Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising R&D Costs - GuruFocus
Decoding Definium Therapeutics Inc (DFTX): A Strategic SWOT Insi - GuruFocus
Definium Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Definium Therapeutics Q4 2025 reports strong R&D investment By Investing.com - Investing.com South Africa
Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Definium Therapeutics Issues Inducement Stock Options to New Hires - TipRanks
Definium Therapeutics Inc: Four pivotal phase III studies near completion, with strong cash reserves and key data readouts ahead - TradingView
Definium Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Definium (DFTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Definium Therapeutics posts full-year 2025 financial results, releases business update - Traders Union
Definium Therapeutics (DFTX) maps late-stage trials in anxiety, depression and autism - Stock Titan
[8-K] Definium Therapeutics, Inc. Reports Material Event | DFTX SEC FilingForm 8-K - Stock Titan
Definium Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Definium Therapeutics (DFTX) Stock Analysis Report | Financials & Insights - Benzinga España
Definium Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Wolfe Research - Defense World
Earnings Preview For Definium Therapeutics - Benzinga
Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
DFTX: Wolfe Research Initiates Coverage with Outperform Rating | - GuruFocus
Definium Therapeutics to Participate at Upcoming Investor Conferences - The Globe and Mail
Definium Therapeutics (DFTX) to Release Quarterly Earnings on Thursday - MarketBeat
Jefferies assigns 65–75% probability of best-in-class efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III - MSN
Avoro Capital Advisors LLC Acquires 5 Million Shares in Definium Therapeutics Inc - GuruFocus
CenterBook Partners LP Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 - The Joplin Globe
Jefferies’ DT120 Confidence and Psychedelic Tailwinds Might Change The Case For Investing In Definium Therapeutics (DFTX) - Sahm
Jefferies Assigns 65-75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III - Bitget
Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III - Insider Monkey
Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 8.3%Still a Buy? - MarketBeat
Should I buy Definium Therapeutics, Inc. (DFTX) - Zacks Investment Research
Commodore Capital reports 7.2% Definium Therapeutics (DFTX) ownership stake - Stock Titan
7 Most Promising Psychedelic Stocks According to Hedge Funds - Insider Monkey
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation After Roger Adsett Joins The Board - Sahm
What is the current Price Target and Forecast for Definium Therapeutics, Inc. (DFTX) - Zacks Investment Research
Is Adsett’s Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Definium Therapeutics Inc Stock (DFTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Definium Therapeutics Inc Stock (DFTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer |
Dec 26 '25 |
Sale |
13.15 |
25,791 |
339,072 |
778,477 |
| Sullivan Mark | Chief Legal Officer |
Dec 26 '25 |
Sale |
13.15 |
11,276 |
148,244 |
282,576 |
3.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):